Paper identifies the statin mechanism as impacting K2 synthesis, contributing to cardiovascular risks.
Few consumers read Expert Review Clinical Pharmacology, but ex-NattoPharma, makers of MenaQ7™ Vitamin K2 as MK-7, feels a new paper published in the March issue should be part of doctors’ conversations with their patients before they prescribe a statin therapy.
The paper[1] states that statins may act as “mitochondrial toxins” with negative effects on the heart and blood vessels not only via the depletion of coenzyme Q10 (CoQ10), but also by inhibiting “the synthesis of vitamin K2, the cofactor for matrix Gla-protein activation, which in turn protects arteries from calcification.
Vitamin K2 plays a critical role in the activation of matrix Gla protein (MGP), which inhibits soft tissue and cardiovascular calcification. MGP is present in bone, blood vessel, lung, heart, and kidney soft tissues. MGP binds calcium and protects blood vessels from calcification, but only when in its active form, which requires adequate intakes of vitamin K2. Unfortunately, statins inhibit vitamin K2 synthesis in the body, thereby accelerating coronary artery calcification, an important marker of the progress of atherosclerosis, according to researchers.
“This new paper speaks directly to statins interrupting the mechanism of action by which vitamin K2 inhibits calcification,” said Hogne Vik, ex-NattoPharma CEO. “Conversely, research clearly demonstrates that increasing dietary vitamin K2, specifically vitamin K2 as menaquinone-7, can improve vitamin K2 levels in the blood and tissues, thus promoting cardiovascular health.”
Artery and vascular benefits
Supporting Vik’s statement, a new study, “Menaquinone-7 Supplementation Improves Arterial Stiffness in Healthy Postmenopausal Women,” published in the journal Thrombosis and Haemostasis[2], demonstrated the positive impact of MenaQ7® brand Vitamin K2 as MK-7 (menaquinone-7) on cardiovascular health through its improvement of arterial flexibility. This study is significant because it is an interventional study with a vitamin K2 dietary supplement, MenaQ7, confirming what previous population-based studies have shown: a positive correlation of vitamin K2 consumption from dietary sources attributes to less arterial calcification and reduced risk of coronary heart disease.
Researchers at the R&D Group VitaK of Maastricht University in the Netherlands monitored 244 healthy post-menopausal women for three years using pulse wave velocity and ultrasound techniques. The participants, aged 55-65 years, were randomly assigned to take 180 mcg of MenaQ7 daily for three years, or placebo capsules. Results confirmed that MenaQ7 Vitamin K2 not only inhibited age-related stiffening of the artery walls, but also made an unprecedented statistically significant improvement of vascular elasticity.
References:
1 Okuyama H, Lagsjoen PH, Hamazaki T, Ogushi Y, Hama R, Kobayashi T, Ochino H. Statins stimulate atherosclerosis and heart failure: pharmacological mechanism. Expert Rev Clin Pharmacol. 2015 Mar;8(2):189-99.
2 Knapen MH et al, Braam LAJL, Drummen NE, Bekers O, Hoeks APG, Vermeer C. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women: double-blind randomised clinical trial. Thrombosis and Haemostasis. 2015 113 5: 1135-1144.
DISCOVER ALL OUR LATEST NEWS
Lynside® Forte Se+ for Skin Protection Against Sun Exposure
Selenium yeast boosts skin defenses against sun damage by fighting oxidative stress, supporting repair, and reducing inflammation for healthier, more resilient skin.
Successful Vital Nutrients Symposium:
Shaping the Future of Healthy Aging
The Vital Nutrients Symposium 2025, held in Kassel, Germany, offered an excellent platform to discuss age-related health, emphasizing emphasizing dietary supplements’ role in prolonging healthspan.
Groundbreaking Vitamin K2 Research Presented at the 7th Osteoporosis Congress in Padova (March 19-21, 2025)
Gnosis recently took an important step in advancing the scientific understanding of vitamin K2 by sponsoring the 7th Osteoporosis Congress in Padova, Italy. Supported by the Italian Ministry of Health, this event brought together esteemed experts in nephrology, osteoporosis, and bone health.
